Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

Market Media Connect retained as Northwest Biotherapeutics' communications agency of record

Northwest Biotherapeutics, Inc., a development stage biotechnology company focused on personalized cancer vaccines to enhance immune system responses to tumors, has retained Market Media Connect as their communications agency of record. Led from its Los Angeles headquarters, Market Media Connect will support Northwest's communication objectives as the company moves into the next phase of its development.

8 Feb 2010

Access Pharmaceuticals initiates Cobalamin technology program for targeted delivery of siRNA therapies

ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.

5 Feb 2010

Cancer Research UK opens Cambridge Cancer Centre

The launch of a centre today (Wednesday) puts Cambridge at the forefront of cancer research, bringing benefits to patients in the South East.

4 Feb 2010

Health Discovery receives final patent infringement payment from Vermillion

Health Discovery Corporation announced today that the Company has received the final payment that was due under the agreement that settled the Company’s patent infringement lawsuit against Vermillion, formerly known as Ciphergen Biosystems, Inc.

4 Feb 2010

Court weighs patents for human genes

The American Civil Liberties Union has sued a genetics company that holds patents on breast- and ovarian-cancer-causing genes, saying their claims on the two genes hinders further research by other companies and scientists, the Associated Press/CBS News reports.

4 Feb 2010

Canary Foundation researcher awarded $11.5M NIH POCRC SPORE grant for early detection ovarian cancer research

Canary Foundation announces its first researcher, Nicole Urban, Sc.D., and collaborators are awarded 5 years of renewed funding from the National Institutes of Health (NIH) for the Pacific Ovarian Cancer Research Consortium (POCRC) Specialized Programs of Research Excellence (SPORE). The SPORE grant will allow Dr. Urban and fellow researchers to continue work in locating tumor markers and developing blood tests to identify and assess risk and early detection of ovarian cancer. The Listwin Family Foundation and Canary Foundation have been funding Dr. Urban's research since 2002.

3 Feb 2010

Scientists develop potential new treatment against ovarian cancer

Scientists at Georgia Tech and the Ovarian Cancer Institute have further developed a potential new treatment against cancer that uses magnetic nanoparticles to attach to cancer cells, removing them from the body.

2 Feb 2010

Global market for oncology drugs is forecast to reach $80 billion by 2050

New Medicine's Oncology KnowledgeBASE (nm/OK) residing at http://nmok.net became available on the Internet 10 years ago and, since then, the oncology field has evolved into one of the most challenging, complex and promising drug development sectors, both in terms of its potential contribution to medicine and to its market opportunities.

29 Jan 2010

Transdermal estrogen therapies: Effective alternatives to oral estrogen and compounded bioidentical hormones

Clinical and experimental evidence suggests that non-patch, transdermal estrogen therapies, such as Divigel® (estradiol gel 0.1%), prescribed for the management of moderate-to-severe hot flashes, including night sweats, associated with menopause are effective alternatives to oral estrogen and compounded bioidentical hormones.

28 Jan 2010

CSCs elimination could hold the key to fight ovarian cancer

Eliminating cancer stem cells (CSCs) within a tumor could hold the key to successful treatments for ovarian cancer, which has been notoriously difficult to detect and treat, according to new findings published this week in the journal Oncogene by Yale School of Medicine researchers.

28 Jan 2010

Abbott declares quarterly dividend of 40 cents per share

Abbott today announced financial results for the fourth quarter ended Dec. 31, 2009.

27 Jan 2010

NCCN updates the NCCN Clinical Practice Guidelines for Oncology for Ovarian Cancer

The National Comprehensive Cancer Network (NCCN) recently updated the NCCN Clinical Practice Guidelines for Oncology™ for Ovarian Cancer to reflect the addition of two preferred combination regimens for a specific cohort of patients based on data from recent clinical research studies.

27 Jan 2010

Access Pharmaceuticals to sell 2.10M shares in registered direct offering

ACCESS PHARMACEUTICALS, INC., today announced that it has entered into definitive agreements with accredited investors to sell in a registered direct offering an aggregate of 2.10 million shares of its common stock at a price of $3.00 per share for aggregate gross proceeds of $6.3 million.

22 Jan 2010

Combining ultrasound with proteomic analyses of blood early-stage ovarian cancer can be identified

Noninvasive contrast-enhanced ultrasound imaging, combined with proteomic analyses of blood samples may help physicians identify early-stage ovarian cancer and save the lives of many women, according to an article published in the February issue of the American Journal of Roentgenology.

22 Jan 2010

BioNumerik Pharmaceuticals commences patient treatment in Tavocept Phase III trial

BioNumerik Pharmaceuticals, Inc. today announced the treatment of the first patients in a global multi-center Phase III clinical trial of Tavocept (BNP7787) in patients with primary adenocarcinoma of the lung, the most common type of lung cancer. In previous studies, Tavocept demonstrated the potential to substantially increase overall and one year patient survival while concurrently preventing and reducing the incidence and severity of common chemotherapy side-effects as compared to other currently available treatments for advanced lung cancer.

21 Jan 2010

IMUC’s ICT-107 vaccine product candidate targets cancer stem cells

ImmunoCellular Therapeutics today announced the results of a study in which it was shown that certain specific antigens are highly expressed on cancer stem cells (CSCs). This suggests that IMUC’s lead cancer vaccine product candidate ICT-107, which targets those antigens, may effectively target not only the cells that make up the bulk of certain cancerous tumors, but also the CSCs that are widely believed to give rise to them and cause their recurrence.

21 Jan 2010

Access Pharmaceuticals provides update on its Cobalamin insulin development program

ACCESS PHARMACEUTICALS, INC. provided an update today on its Cobalamin™ oral drug delivery product development programs. The proprietary Cobalamin™ technology utilizes the body's natural vitamin B12 oral uptake mechanism to facilitate oral absorption of pharmaceuticals by a "Trojan horse" mechanism.

20 Jan 2010

Breast cancer and ovarian cancer tests not appropriate for all women, say experts

A genetic mutation can significantly increases a woman's risk of developing breast cancer and ovarian cancer. But does that mean everyone should be tested?

18 Jan 2010

Sword Diagnostics launches Raman detection system for ultrasensitive immunoassays

Sword Diagnostics announced today the launch of its proprietary Raman detection system for ultrasensitive immunoassays. The system provides researchers with greater sensitivity which enables more accurate testing of low abundance markers.

18 Jan 2010

European approval for Abbott's new ovarian cancer diagnostic test

A new diagnostic tool, which studies show can aid in determining the risk of whether a pelvic mass is benign or malignant, is now available in Europe. This simple blood test is expected to help in the assessment of epithelial ovarian cancer, the most lethal form of gynecological cancer.

14 Jan 2010

Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

Market Media Connect retained as Northwest Biotherapeutics' communications agency of record

Access Pharmaceuticals initiates Cobalamin technology program for targeted delivery of siRNA therapies

Cancer Research UK opens Cambridge Cancer Centre

Health Discovery receives final patent infringement payment from Vermillion

Court weighs patents for human genes

Canary Foundation researcher awarded $11.5M NIH POCRC SPORE grant for early detection ovarian cancer research

Scientists develop potential new treatment against ovarian cancer

Global market for oncology drugs is forecast to reach $80 billion by 2050

Transdermal estrogen therapies: Effective alternatives to oral estrogen and compounded bioidentical hormones

CSCs elimination could hold the key to fight ovarian cancer

Abbott declares quarterly dividend of 40 cents per share

NCCN updates the NCCN Clinical Practice Guidelines for Oncology for Ovarian Cancer

Access Pharmaceuticals to sell 2.10M shares in registered direct offering

Combining ultrasound with proteomic analyses of blood early-stage ovarian cancer can be identified

BioNumerik Pharmaceuticals commences patient treatment in Tavocept Phase III trial

IMUC’s ICT-107 vaccine product candidate targets cancer stem cells

Access Pharmaceuticals provides update on its Cobalamin insulin development program

Breast cancer and ovarian cancer tests not appropriate for all women, say experts

Sword Diagnostics launches Raman detection system for ultrasensitive immunoassays

European approval for Abbott's new ovarian cancer diagnostic test

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Newsletters you may be interested in